Dr. Volker Hoffmann MD
Partner/Owner, Diagnostic Imaging Center
Member of the Healthcare Council
Council Member Biography
Volker Hoffmann, MD, is a Diagnostic and Interventional Radiologist and one of the three owners of Diagnostic Imaging Center, a large private imaging center.
He was a Product Manager and Medical Consultant at Strategic Marketing of the Global Business Unit Diagnostics at Schering AG, (now BayerScheringPharma) Germany. Dr. Hoffmann's main area of interest is breast imaging, optical imaging as well as MR imaging (heart, liver, and blood pool). He also has knowledge of in-licensing, business case models, and development plans for all diagnostic modalities including MR, ultrasound, CT, x-ray angiography, and partially nuclear medicine. For several years, Dr. Hoffmann was in clinical development where he was responsible for Phase I/II/III and IV trials in the US and Europe for MR and x-ray imaging agents.
(This is me - Update Profile)
Employment History
- 2006 - Unspecified
- Partner/Owner, Diagnostic Imaging Center
- 2001 - 2005
- Product Manager and Medical Advisor, BAYER SCHERING PHARMA AG
- 1996 - 2000
- Study Director, NYCOMED AMERSHAM
GLG NewsSM Analyses by Volker Hoffmann
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
NSF (Nephrogenic Systemic Fibrosis) - Gadoxetic Acid (Primovist)
October 9, 2007
Study Finds NSF More Common Than Previously Reported | www.dimag.com
Nephrogenic systemic fibrosis is becoming a severe problem for radiologist and industry as it may prevent physicians from using gadolinium containing contrast agents fearing that they induce nephrogenic systemic fibrosis even in patients without known kidney disease. A stable contrast agent with almost no release of gadolinium may be a solution: gadoxetic acid, sold in Europe and Asia as Primovist.
-
IMDS - CTML - Value without contrast agents?
May 14, 2007
Imaging Diagnostic Systems Breast Scanner Performance Upgrade Program Nearing Completion | www.medicalnewstoday.com
The recent upgrade of the Computed Tomography Laser Mammography (CTLM(R)) system will only added minor details. The question whether this system without any contrast agent is of any value has not been answered so far.
-
Impropved pancreatic duct imaging in MR - small market for Secretin
May 14, 2007
Repligen Reports Positive Phase 2 Clinical Trial Results Of Secretin For MRI Imaging Of The Pancreas | www.medicalnewstoday.com
Pancreatic duct imaging is currently done with a heavily weighted T2 sequence that requires water in the duct for imaging. Increased production of pancreatic juice may make imaging easier. This is however a very small niche market which by itself will not allow survival of RG1068.
GLG Study Groups with Volker Hoffmann(?)
| Study Group Name | No. Members |
|---|---|
| Physicians (Germany) | 1198 |
| Radiologists (EU) | 255 |
| Diagnostic Radiologists (EU) | 141 |
| Diagnostic Radiologists :Nuclear Radiology | 138 |
| Interventional and Vascular Radiologists (EU) | 72 |
GLG Live Meetings with Volker Hoffmann(?)
Volker Hoffmann has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.